Hence, miR-184 exerts an impact on pulmonary fibrosis via the TGF-β1/PI3K-AKT pathway, leading to the hypothesis that upregulation of miR-184 may mitigate fibrotic processes, thereby proposing a novel approach for managing IPF (Table 4). Here, AKT1 is linked to idiopathic pulmonary fibrosis.